Title:
ANTI-PD-L1 ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION USED IN COMBINATION WITH ANTI-VEGF ANTIBODIES AND PACLITAXEL
Document Type and Number:
WIPO Patent Application WO/2023/145834
Kind Code:
A1
Abstract:
The present disclosure relates to a pharmaceutical composition containing paclitaxel, anti-VEGF antibodies, and anti-PD-L1 antibodies.
More Like This:
Inventors:
TAKAHASHI KOJI (JP)
AKAMATSU AYUMI (JP)
TAKEMOTO SHINYA (JP)
IWAI TOSHIKI (JP)
HARA FUMIKATA (JP)
YONEMORI KAN (JP)
SHIEN TADAHIKO (JP)
AKAMATSU AYUMI (JP)
TAKEMOTO SHINYA (JP)
IWAI TOSHIKI (JP)
HARA FUMIKATA (JP)
YONEMORI KAN (JP)
SHIEN TADAHIKO (JP)
Application Number:
PCT/JP2023/002476
Publication Date:
August 03, 2023
Filing Date:
January 26, 2023
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
GENENTECH INC (US)
GENENTECH INC (US)
International Classes:
A61K39/395; A61K31/337; A61P35/00
Foreign References:
| JP2021167312A | 2021-10-21 |
Other References:
ANONYMOUS: "A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION)", CLINICALTRIALS.GOV ID NCT04732598, 28 February 2021 (2021-02-28), XP093081427, Retrieved from the Internet
HARA, FUMIKATA: "New development of immune checkpoint inhibitors in breast cancer Development of immune checkpoint inhibitors in hormone receptor-positive breast cancer and HER2-positive breast cancer", JAPANESE JOURNAL OF BREAST CANCER., vol. 36, no. 3, 1 January 2021 (2021-01-01), pages 173 - 179, XP009548128, ISSN: 0911-2251
SCHREIBER ANNA R., KAGIHARA JODI A., WEISS JENNIFER A., NICKLAWSKY ANDREW, GAO DEXIANG, BORGES VIRGINIA F., KABOS PETER, DIAMOND J: "Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials", FRONTIERS IN ONCOLOGY, vol. 11, XP093081429, DOI: 10.3389/fonc.2021.640690
MORIMOTO, MASAMI ET AL.: "GP-3-38-100: Treatment results of paclitaxel/bevacizumab therapy for HER2-negative hormone receptor-positive advanced/recurrent breast cancer", PROGRAMS AND ABSTRACTS OF THE 26TH ANNUAL MEETING OF THE JAPANESE BREAST CANCER SOCIETY; MAY 16TH - 19TH, 2018, JAPANESE BREAST CANCER SOCIETY, JP, vol. 26, 1 January 2018 (2018-01-01) - 19 May 2018 (2018-05-19), JP, pages 739, XP009548190
OZAKI, YUKINORI: "Checkpoint blockade strategies in hormone receptor positive and/or HER2-positive breast cancer", CLINICAL ONCOLOGY, vol. 24, no. 2, 2019, pages 137 - 142, XP009547711
HARA, FUMIKATA: "New development of immune checkpoint inhibitors in breast cancer Development of immune checkpoint inhibitors in hormone receptor-positive breast cancer and HER2-positive breast cancer", JAPANESE JOURNAL OF BREAST CANCER., vol. 36, no. 3, 1 January 2021 (2021-01-01), pages 173 - 179, XP009548128, ISSN: 0911-2251
SCHREIBER ANNA R., KAGIHARA JODI A., WEISS JENNIFER A., NICKLAWSKY ANDREW, GAO DEXIANG, BORGES VIRGINIA F., KABOS PETER, DIAMOND J: "Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials", FRONTIERS IN ONCOLOGY, vol. 11, XP093081429, DOI: 10.3389/fonc.2021.640690
MORIMOTO, MASAMI ET AL.: "GP-3-38-100: Treatment results of paclitaxel/bevacizumab therapy for HER2-negative hormone receptor-positive advanced/recurrent breast cancer", PROGRAMS AND ABSTRACTS OF THE 26TH ANNUAL MEETING OF THE JAPANESE BREAST CANCER SOCIETY; MAY 16TH - 19TH, 2018, JAPANESE BREAST CANCER SOCIETY, JP, vol. 26, 1 January 2018 (2018-01-01) - 19 May 2018 (2018-05-19), JP, pages 739, XP009548190
OZAKI, YUKINORI: "Checkpoint blockade strategies in hormone receptor positive and/or HER2-positive breast cancer", CLINICAL ONCOLOGY, vol. 24, no. 2, 2019, pages 137 - 142, XP009547711
Attorney, Agent or Firm:
TSUKUNI & ASSOCIATES et al. (JP)
Download PDF: